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background:  This study evaluated the impact of time-in-therapeutic ranges (TTR) on healthcare resource utilization and costs among 
nonvalvular atrial fibrillation (NVAF) patients treated with warfarin.
Methods:  Patients with NVAF, warfarin treatment, and international normalized ratios (INR) between 1/1/2004 and 8/31/2013 were 
identified from an electronic medical record database and grouped into 2 cohorts, those with TTR <60% and TTR ≥60%. Patient 
demographics, clinical characteristics, and healthcare resource utilization and costs during a 12-month follow-up period after the first 
INR test were evaluated. Multivariable regressions were used to compare healthcare costs of cohorts while controlling for key patient 
characteristics.
Results:  Mean ages of NVAF patients in the low (n=1,595, 53% male) and high (n=1,356, 51% male) TTR cohorts were 71.1 and 72.2 
years, respectively. Charlson Comorbidity Index (2.9 vs. 2.3, p<0.001) and CHADS2 (2.2 vs. 2.0, p<0.001) scores were higher for NVAF 
patients with low TTR vs. high TTR. All cause, stroke-related, and bleed-related healthcare costs were higher for NVAF patients with low 
TTR vs. high TTR. Multivariable regression results showed consistent findings.
conclusion:  Approximately 54% of NVAF patients had warfarin TTR <60%. These patients had higher total healthcare, stroke- and 
bleeding-related costs. Further research, quality improvements or alternative treatment approaches may benefit NVAF patients on warfarin 
and reduce healthcare costs.
Table. Healthcare Resource Costs of NVAF Patients with Low and High Warfarin Time-in-Therapeutic Ranges (TTR)
Resource/Cost Low (<60% TTR) Mean [SD]
High (≥60% TTR) 
Mean [SD] p-value
All Cause Total Cost $16,939 [$29,199] $9,233 [$18,206] <0.001
All Cause Hospital Cost $12,820 [$24,898] $6,754 [$15,638] <0.001
Stroke-related Total Cost $1,707 [$9,639] $740 [$5,313] 0.001
Stroke-related Hospital Cost $1,382 [$8,157] $581 [$4,330] 0.001
Bleed-related Total Cost $1,853 [$9,552] $1,120 [$7,734] 0.024
Bleed-related Hospital Cost $1,544 [$8,225] $938 [$6,695] 0.030
